Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER2): final results of a multicentre, prospective, observational study
Source: View publication →
The PARTNER2 study demonstrated that among gay male serodifferent couples, there were zero linked HIV transmissions during periods of condomless sex when the HIV-positive partner maintained a viral load suppressed by antiretroviral therapy.
Key Findings
Study Design
Study Limitations
Clinical Significance
These findings provide high-level evidence that effective antiretroviral therapy resulting in viral suppression renders an individual sexually noninfectious. This supports the global U=U campaign, reduces HIV-related stigma, and guides clinical counseling by clarifying that condomless sex does not pose a risk of HIV transmission for serodifferent couples when the HIV-positive partner is virally suppressed.
Historical Context
The PARTNER2 study served as the essential follow-up to the original PARTNER1 study, which provided strong evidence for HIV prevention via treatment in heterosexual couples but had narrower statistical power to definitively rule out transmission risks in gay male couples practicing anal sex. Together, these trials revolutionized the clinical and public health understanding of HIV as a chronic, manageable, and non-transmissible condition under effective treatment.
Guided Discussion
High-yield insights from every perspective
Based on the biological mechanisms of HIV replication and the results of the PARTNER2 study, how does effective antiretroviral therapy (ART) achieve a state where the risk of sexual transmission is effectively zero?
Key Response
ART works by inhibiting key enzymes—reverse transcriptase, integrase, and protease—which prevents the production of new virions. When ART is consistently taken, the viral load in both the blood and genital secretions falls below the limit of detection (typically <50 copies/mL, though PARTNER2 used a threshold of <200 copies/mL). At these levels, the concentration of virus is insufficient to establish an infection in the mucosal tissues of a partner, forming the basis for the 'Undetectable = Untransmittable' (U=U) principle.
A serodifferent gay couple presents to the clinic; the HIV-positive partner has been virally suppressed for 12 months. They ask if they still need to use condoms to prevent HIV transmission. According to PARTNER2, what are the three essential criteria you must confirm before advising them that the risk is zero?
Key Response
Clinical application of PARTNER2 requires confirming: 1) The HIV-positive partner is on a stable ART regimen with excellent adherence; 2) The viral load is suppressed (defined as <200 copies/mL) and has been for at least six months; and 3) Viral load monitoring is performed regularly (every 4-6 months). Notably, PARTNER2 found that the presence of other STIs did not lead to any linked HIV transmissions, though condom use is still recommended for STI prevention.
PARTNER2 specifically focused on MSM (men who have sex with men). How did the statistical power and the upper limit of the 95% confidence interval in this study provide more definitive evidence for this population compared to the earlier PARTNER1 study?
Key Response
Anal intercourse carries a significantly higher per-act transmission risk than vaginal intercourse. PARTNER1 lacked sufficient power to make definitive claims for MSM. PARTNER2 collected data on over 76,000 condomless sex acts specifically in MSM couples. The study reported zero linked transmissions, and the upper bound of the 95% confidence interval for the transmission rate was only 0.23 per 100 couple-years, providing the robust statistical confidence needed to recommend U=U for anal sex as confidently as for vaginal sex.
How should the 'zero linked transmissions' result of PARTNER2 shift the clinical dialogue from 'risk reduction' to 'risk elimination,' and what are the broader public health implications for HIV stigma and PrEP utilization?
Key Response
The findings transition HIV management from a harm-reduction model to a definitive prevention model. Clinicians can now state with scientific certainty that suppressed viral load eliminates the risk of sexual transmission. This helps de-stigmatize HIV-positive individuals by removing the 'vector' label. It also allows for nuanced discussions regarding PrEP; if the HIV-positive partner is consistently suppressed, the HIV-negative partner may choose to discontinue PrEP, assuming the relationship is monogamous and suppression is verified.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
PARTNER2 utilized phylogenetic analysis to verify the source of any new HIV infections. Critically evaluate why this methodology was essential to the study's validity and what 'linked' versus 'unlinked' infections reveal about the study cohort's behavior.
Key Response
In a cohort of serodifferent couples, new infections in the negative partner can occur from outside the primary relationship. Phylogenetic analysis compares the pol and env sequences of the virus from both partners. If the sequences are significantly different, the infection is 'unlinked.' In PARTNER2, 15 new infections occurred, but all were unlinked to the suppressed partner. Without phylogenetics, the study would have falsely reported 15 failures of ART to prevent transmission, leading to incorrect conclusions about the efficacy of U=U.
As a peer reviewer, how would you evaluate the threat of 'attrition bias' in PARTNER2, considering the long-term follow-up required to observe transmission events in a prospective cohort?
Key Response
A tough reviewer would flag that couples who remained in the study (783 couples provided data) might be more adherent to ART or more health-conscious than those lost to follow-up. If the couples who dropped out were those with poor adherence or fluctuating viral loads, the 'zero transmission' result might be over-optimistic. However, the study's large number of sex acts and the use of 'couple-years of follow-up' as the denominator helps mitigate this, but the editor would require a transparent sensitivity analysis of those lost to follow-up.
Based on the PARTNER2 findings, should international guidelines (e.g., WHO or CDC) move from recommending ART 'to reduce transmission' to 'to prevent transmission,' and how does this impact the 'Level of Evidence' for MSM populations?
Key Response
PARTNER2 provides 'Level 1a' evidence (large prospective multicentre study) that ART prevents transmission. Current CDC and WHO guidelines have already been updated to reflect that 'effectively no risk' exists when U=U is achieved. The PARTNER2 results specifically allow guidelines to align the recommendations for MSM with those for heterosexual couples, removing the previous caveat that data for anal sex was less certain. It justifies a Grade 1A recommendation for U=U as a primary prevention strategy.
Clinical Landscape
Noteworthy Related Trials
HPTN 052
Tested
Early initiation of antiretroviral therapy (ART)
Population
HIV-serodifferent heterosexual couples
Comparator
Delayed initiation of ART
Endpoint
Linked HIV transmission to the HIV-uninfected partner
PARTNER1
Tested
Suppressive antiretroviral therapy (ART)
Population
HIV-serodifferent couples (men who have sex with men and heterosexuals)
Comparator
Observational cohort (condomless sex)
Endpoint
Linked HIV transmission to the HIV-uninfected partner
Opposites Attract
Tested
Suppressive antiretroviral therapy (ART)
Population
HIV-serodifferent gay male couples
Comparator
Observational cohort (condomless sex)
Endpoint
Linked HIV transmission to the HIV-uninfected partner
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis